<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endogenous level of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) is increased in the brain following the <z:hpo ids='HP_0001297'>stroke</z:hpo>, and deactivation of NO synthase has been shown to attenuate its destructive actions in animal <z:hpo ids='HP_0001297'>stroke</z:hpo> models using middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) procedures </plain></SENT>
<SENT sid="1" pm="."><plain>However, little is known about the effects of NO in cerebral vascular integrity and <z:hpo ids='HP_0000969'>edema</z:hpo> during <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Here we investigated whether NO plays any role in the progression of blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) disruption and <z:hpo ids='HP_0000969'>edema</z:hpo> formation in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury </plain></SENT>
<SENT sid="3" pm="."><plain>Intraperitoneal administration of NO substrate l-arginine (300mg/kg), or NOS inhibitor (l-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, 1mg/kg), was done in <z:mpath ids='MPATH_458'>normal</z:mpath> rats at 20min before a 60-min MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>Mean arterial blood pressures (MAP) and regional cerebral blood flow (rCBF) were continuously recorded during experiment </plain></SENT>
<SENT sid="5" pm="."><plain>Neurological deficit score (NDS) was evaluated 12h after termination of MCAO followed with evaluations of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> volume (CIV), <z:hpo ids='HP_0000969'>edema</z:hpo> formation and cerebral vascular permeability (CVP), as determined by the Evans blue dye extravasations (EBE) technique </plain></SENT>
<SENT sid="6" pm="."><plain>No significant changes were observed in the values of MAP and rCBF with l-arginine or l-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or reperfusion periods </plain></SENT>
<SENT sid="7" pm="."><plain>There was a 75-85% reduction in rCBF in during MCAO which returned back to its pre-occlusion level during reperfusion </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> with or without l-arginine augmented NDS (4.00±0.44 and 3.00±0.30), in conjunction with increased CIV (518±57mm(3) and 461±65mm(3)), provoked <z:hpo ids='HP_0000969'>edema</z:hpo> (3.09±0.45% and 3.30±0.49%), and elevated EBE (8.28±2.04μg/g and 5.09±1.41μg/g) </plain></SENT>
<SENT sid="9" pm="."><plain>Inhibition of NO production by l-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> significantly improved NDS (1.50±0.22), diminished CIV (248±56mm(3)), <z:hpo ids='HP_0000969'>edema</z:hpo> (1.18±0.58%) and EBE (1.37±0.12μg/g) </plain></SENT>
<SENT sid="10" pm="."><plain>This study reconfirms the cerebroprotective properties of reduced tissue NO during <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, and it also validates the deleterious actions of increased NOS activity on the disruption of cerebral microvascular integrity and <z:hpo ids='HP_0000969'>edema</z:hpo> formation of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injuries in <z:mpath ids='MPATH_458'>normal</z:mpath> rat, without changing arterial blood pressure or blood flows to ischemic regions </plain></SENT>
</text></document>